Robinhood shares gain on Q2 beat, as user and crypto growth accelerate
Cathie Wood’s ARK ETFs have released their daily trades for Wednesday, February 26th, 2025, revealing a continued strategy of selective buying and selling across various sectors. The most significant transaction of the day was the purchase of 75,340 shares of ABSCI CORP (NASDAQ:ABSI) through the ARKG ETF, totaling approximately $302,866. This move comes after a similar acquisition on Tuesday, indicating a growing position in the biotech company.
Conversely, ARK ETFs also sold 24,672 shares of ACCOLADE INC (NASDAQ:ACCD) through the ARKG ETF, amounting to $171,470. This sale follows a larger divestment from the previous day, suggesting a scaling back of ARK’s investment in the healthcare technology firm.
This pattern of trades aligns with ARK’s recent activity. Earlier in the week, ARK increased its stakes in companies like COINBASE GLOBAL INC (NASDAQ:COIN) and IRIDIUM COMMUNICATIONS INC (NASDAQ:IRDM), while reducing exposure to ACCOLADE INC and DRAFTKINGS INC (NASDAQ:DKNG). The frequent trading in these stocks reflects ARK’s dynamic investment approach, adapting to market conditions and company performance.
In addition to these trades, the ARK ETFs have also shown a consistent interest in BEAM THERAPEUTICS INC (NASDAQ:BEAM), with purchases across multiple days, indicating a bullish outlook on the genetic medicines company. On the sell side, ARK has been reducing its holdings in ADAPTIVE BIOTECHNOLOGIES CORP (NASDAQ:ADPT) and ROCKET LAB USA INC (NASDAQ:RKLB), suggesting a strategic shift away from these stocks.
Investors following Cathie Wood’s ARK ETFs are witnessing an investment strategy that remains agile, with the fund’s management team actively seeking opportunities and managing risks across a range of innovative companies. As always, market participants will be watching closely to see how these trades play out in the context of ARK’s broader portfolio strategy.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.